Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

The predictive utility of circulating PCSK9 levels on diabetes mellitus

(2021) Jia Peng et al.   Cardiovascular Diabetology

Inclisiran: First Approval

(2021) Yvette N. Lamb   DRUGS

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia

(2020) G. Kees Hovingh et al.   CIRCULATION

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9

(2019) Charles A. German et al.   BIODRUGS

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

(2019) R. Scott Wright et al.   MAYO CLINIC PROCEEDINGS

Effect of Evolocumab on Lipoprotein Particles

(2018) Peter P. Toth et al.   AMERICAN JOURNAL OF CARDIOLOGY

Management of Statin Intolerance in 2018: Still More Questions Than Answers

(2018) Peter P. Toth et al.   American Journal of Cardiovascular Drugs

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

(2018) Michael D. Shapiro et al.   ANNALS OF INTERNAL MEDICINE

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

(2018) Manfredi Rizzo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Assessment of the 1% of Patients with Consistent

(2018) Harold E. Bays et al.   CARDIOVASCULAR DRUGS AND THERAPY

Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation

(2018) Angelos D. Karagiannis et al.   Current Atherosclerosis Reports

Inclisiran for the treatment of dyslipidemia

(2018) Toshiyuki Nishikido et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Role of Nutraceuticals in Statin Intolerant Patients

(2018) Maciej Banach et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

(2018) Wieneke Dijk et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

(2018) Aaron D. Springer et al.   Nucleic Acid Therapeutics

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

(2018) Lawrence A. Leiter et al.   DIABETES CARE

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab

(2018) Arman Qamar et al.   JAMA Cardiology

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables

(2017) Theodosios D. Filippatos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

(2017) Jerome D. Cohen et al.   Journal of Clinical Lipidology

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

(2017) Xiulong Shen et al.   NUCLEIC ACIDS RESEARCH

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

(2017) Christopher P. Cannon et al.   JAMA Cardiology

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

(2016) Yajnavalka Banerjee et al.   ATHEROSCLEROSIS

Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor

(2016) Xiangang Huang et al.   BIOCONJUGATE CHEMISTRY

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective

(2016) Gerald F. Watts et al.   CIRCULATION

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

(2016) Peter P. Toth et al.   Lipids in Health and Disease

Statin use and the risk of developing diabetes: a network meta-analysis

(2016) Divyesh Thakker et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Preclinical and clinical development of siRNA-based therapeutics

(2015) Gulnihal Ozcan et al.   ADVANCED DRUG DELIVERY REVIEWS

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

(2015) Terry A. Jacobson et al.   Journal of Clinical Lipidology

Knocking down disease: a progress report on siRNA therapeutics

(2015) Anders Wittrup et al.   NATURE REVIEWS GENETICS

Prevalence of dyslipidemia and associated risk factors in Turkish adults

(2014) Fahri Bayram et al.   Journal of Clinical Lipidology

Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

(2014) Jayaprakash K. Nair et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statin Use And Risk Of Developing Diabetes In Cardiovascular Disease: Systematic Literature Review And Meta-Analysis

(2014) D. Thakker et al.   VALUE IN HEALTH

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

(2013) Peter P. Toth et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality

(2013) Marcin Barylski et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

(2013) Maciej Banach et al.   CURRENT PHARMACEUTICAL DESIGN

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

(2013) Manfredi Rizzo et al.   CURRENT PHARMACEUTICAL DESIGN

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Argonaute proteins: functional insights and emerging roles

(2013) Gunter Meister   NATURE REVIEWS GENETICS

Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study

(2010) Egle Corrado et al.   CORONARY ARTERY DISEASE

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Ethnic differences in serum lipoproteins and their determinants in South African women

(2010) Julia H. Goedecke et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis

(2009) Manfredi Rizzo et al.   ATHEROSCLEROSIS

Origins and Mechanisms of miRNAs and siRNAs

(2009) Richard W. Carthew et al.   CELL

Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis

(2009) S. N. Rajpathak et al.   DIABETES CARE

On the road to reading the RNA-interference code

(2009) Haruhiko Siomi et al.   NATURE

Knocking down barriers: advances in siRNA delivery

(2009) Kathryn A. Whitehead et al.   NATURE REVIEWS DRUG DISCOVERY

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

(2009) Aimee L. Jackson et al.   NATURE REVIEWS DRUG DISCOVERY

Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes

(2008) M. Rizzo et al.   DIABETIC MEDICINE

Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles

(2008) Frank Alexis et al.   MOLECULAR PHARMACEUTICS

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

(2008) Akin Akinc et al.   NATURE BIOTECHNOLOGY

Chemical Modification of siRNAs for In Vivo Use

(2008) Mark A. Behlke   OLIGONUCLEOTIDES

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease

(2007) Manfredi Rizzo et al.   ATHEROSCLEROSIS